10x Genomics, CHUV Partner on Single Cell Cancer Biomarker Study
10x Genomics and Lausanne University Hospital (CHUV) launched a research collaboration to advance diagnostic applications of single cell…
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically…
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
Alps Group Inc Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia’s First…
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically…
Alps Group launches cancer organoid program | ALPS SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN…
Alps Group launches PDO cancer program in Malaysia
Alps Group (Nasdaq: ALPS) signed a Research and Collaboration Agreement with Axiocell Biotech’s…
Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer
Roche Pharma India has announced the launch of Tecentriq® SC (atezolizumab) in India, introducing the country’s first subcutaneous…
FDA Approves Roche PTEN Companion Diagnostic for Prostate
Roche has received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA PTEN (SP218) RxDx…
Advancing Precision Oncology Novartis Launches India’s First Approved Radioligand Therapy for Prostate Cancer
About Us ‘Telugu Times’ was started as the First Global Telugu Newspaper in USA in July 2003 by…
India gets first approved radioligand therapy for prostate cancer | Health News
Months after exiting its listed Indian subsidiary, Novartis has reinforced its commitment to the country’s innovation medicines…
Novartis India launches Pluvicto for prostate cancer treatment
New Delhi: Novartis India on Monday announced the launch of Pluvicto, a precision radiotherapy for prostate cancer. Pluvicto…
Novartis launches Pluvicto®, the Country’s First Regulatory Authority Approved Radioligand Therapy for Advanced Prostate Cancer
Novartis India announced the launch of Pluvicto(lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority-approved radioligand therapy for…